Table 4.
Cox regression analysis for the prediction of overall survival in patients with urothelial bladder cancer (n = 88, number of events = 32)
| Overall Survival | Univariate analysis | Multivariate analysisa | ||||
|---|---|---|---|---|---|---|
| p-value | HR | 95% CI | p-value | HR | 95% CI | |
| RNY1, low vs high | 0.013 | 2.49 | 1.22–5.08 | 0.615 | 1.24 | 0.55–2.80 |
| RNY3, low vs high | 0.009 | 2.60 | 1.27–5.33 | 0.400 | 1.43 | 0.62–3.26 |
| RNY4, low vs high | 0.053 | 2.03 | 0.99–4.15 | 0.847 | 1.08 | 0.49–2.41 |
| RNY5, low vs high | 0.545 | 0.80 | 0.40–1.63 | 0.531 | 0.80 | 0.39–1.62 |
| MIBC vs. NMIBC | 4.9e-04 | 4.05 | 1.85–8.90 | 0.055 | 2.86* | 0.98–8.36 |
| pN-stage, pN1 vs pN0 | 0.003 | 2.89 | 1.44–5.84 | 0.641 | 1.24* | 0.50–3.05 |
| cM-stage, M1 (n = 2) vs M0 | 0.001 | 12.87 | 2.71–61.16 | x | x | x |
| Grade, G3 vs G1 + G2 | 0.021 | 2.39 | 1.14–5.01 | 0.575 | 1.29* | 0.55–3.09 |
Comments: aIn case of every YRNA data is shown for separate multivariate model with “MIBC vs NMIBC”, pN-Stage and Grade as co-variates; *HR, p-value, 95% CI shown for multivariate model with RNY1. Other YRNAs (RNY3, RNY4, RNY5) showed similar results
Analysis for YRNAs is based on the best cut-off, the same as in Kaplan-Meier/log-rank analysis: RNY1–0.082, RNY3–0.181, RNY4–0.338, RNY5–1.151. Abbreviations: MIBC muscle-invasive bladder cancer, NMIBC non-muscle-invasive bladder cancer